Project Grant R43DK143839
Award Date 9/15/25
Completion Date 8/31/26
Dollars Obligated $296K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Evanston, IL 60202, USA
Similar Awards
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $314,355 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Angiotensin Therapeutics Inc., a biotechnology company located in Evanston, Illinois. The funding supports research to develop a soluble form of the enzyme Angiotensin Converting Enzyme 2 (ACE2) as a potential treatment for delayed graft function (DGF), a form of acute kidney injury that...
- This federal Project Grant award of $3,010,432 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), is funding research to develop mitoprotective therapies for the treatment of acute kidney injury (AKI). The key objectives of this research are to characterize a novel mitochondrial protein target, phospholipid scramblase 3 (PLSCR3), and evaluate pharmacological activators...
- This $755,853.00 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to target the pathophysiology of sickle cell-related kidney disease using SGLT2 inhibitors. The key products and services to be delivered through this funding include: Evaluating whether the SGLT2 inhibitor empagliflozin improves biomarkers of kidney function and injury, as well as measures of kidney perfusion, oxygenation, and fibrosis using functional...
- This Project Grant award of $349,325 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The goal of the award is to develop an orally-available, effective, and well-tolerated drug to treat autosomal dominant polycystic kidney disease (ADPKD) by targeting the arginine-polyamine pathway. The awardee, Regennova, Inc., a small disadvantaged business located in North...
- This federal Project Grant award, in the amount of $531,999.00, was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award is supporting research focused on understanding the role of alternative splicing in the proximal tubules of the kidney and its relationship to the progression of diabetic kidney disease. The research will investigate how diabetes...
- This $596,345 federal Project Grant was awarded on May 1, 2025 by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant supports research conducted by the Augusta University Research Institute, Inc. in Augusta, GA to investigate the molecular mechanisms underlying diabetic renal hypertrophy and its impact on acute kidney injury (AKI) susceptibility in diabetic...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $200,000 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to The Washington University in St. Louis. The goal of this R56 award is to delineate the molecular mechanism regulating autophagy in Autosomal Dominant Tubulointerstitial Kidney Disease (ADTKD) caused by UMOD mutations. The university will use CRISPR/Cas9 technology to generate the first...
- This Project Grant award of $389,754 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to assess the therapeutic potential of a peptide derived from collagen XVIII for treating lung fibrosis associated with systemic sclerosis (scleroderma). The project aims to evaluate the anti-fibrotic effects of this peptide in a murine model of lung fibrosis, as well as identify the minimal effective dose, optimal...
- This $2,833,514 Project Grant was awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant, titled "Renal Metabolism in AKI", will fund research to investigate changes in kidney metabolism in sepsis-associated acute kidney injury (AKI) and their impact on kidney tubule injury and recovery. The University of California, San Diego (UCSD) is the awardee...
- This Project Grant award, funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research to develop a novel kidney-draining lymph node-targeted nanotherapeutic for treating crescentic glomerulonephritis (CGN), a severe immune-mediated kidney condition. The $2,466,907 award to Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare System...